Nanotechnology in Biomedical Research
Transcript of Nanotechnology in Biomedical Research
-
7/24/2019 Nanotechnology in Biomedical Research
1/17
Nanotechnology in BioMedical SciencesNanotechnology in BioMedical Sciences
Earl J. Bergey, Bruce A. Holm, Tapas De, Yudhisthira Sahoo, DavidRodman,Christopher Friend, Indrajit Roy, and Paras N. Prasad
Institute for Lasers, Photonics and Biophotonics and
School of Medicine and Biomedical SciencesThe State University of New York at Buffalo
Buffalo, New York 14260
-
7/24/2019 Nanotechnology in Biomedical Research
2/17
AbstractAbstract
Nanotechnology is rapidly expanding into the biomedical field. At the Institute for Lasers,Photonics and Biophotonics, research in nanotechnology has focused on the development ofmultifunctional nano-sized particles we have termed as nanoclinics. They consist of a nanosizedbubble fabricated to carry therapeutic or diagnostic components to targeted cells. The outer surfaceof these particles can be functionalized to incorporate biologically active targeting agent. Thistechnology provides a platform for the development of new imaging, diagnostic and therapeuticmodalities. For bioimaging and diagnostics, nanoclinics are fabricated containing rare-earth ions,which exhibit two-photon, anti-stokes luminescence by frequency up-converting infrared to visiblelight. At the Institute, we have successfully prepared the phosphors containing nanoclinics having asize ~25nm with a silica shell around it which helps in aqueous dispersability and also allows
functionalization for covalent attachment of bioprobes for targeting. The coupling of specificpeptides, proteins or nucleic acid sequences to the silica shell will allow for the selective detectionof biological entities that will have applications in microscopy, flow cytometry, ELISA andDNA/RNA hybridization systems. This adaptable nanoparticle platform was used to developnanoclinics, which selectively target specific cell or tissue types. These targeted nanoclinics cancarry therapeutic drugs, DNA for gene transfer therapy, or provide externally activated therapy as inphotodynamic therapy or magnetic field activation. The core of our prototypic nanoclinic consists
of either Fe2O3 or Fe3O4 to which a fluorophore is coupled. These nanoparticles are encased ineither silica or by a fatty acid bilayer, respectively. The final step is to attach the targeting ligandLH-RH (luteinizing hormone-releasing hormone) to complete the nanoclinic. This design allowsfor detection of specific cells or tissues using standard MRI equipment and can be usedtherapeutically with the same instrumentation (stronger DC magnetic field). These nanoclinicscause magnetocytolysis of LH-RH receptor-positive cancers, in vitro, in a DC magnetic field..These therapeutic nanoclinic systems could provide the clinician ith a ne tool in the fight againsthuman diseases.
-
7/24/2019 Nanotechnology in Biomedical Research
3/17
NanoClinicsNanoClinics
Composed of !ilica or Ca"#$shell encapsulating , Rare-earth
elements, iron o%ide, D&' or DrugsLess than ( nm in size *tuna+le)
"roduced +y a reverse micelle process
!urface can +e modified *targeting)
Rare arth elements fficient upconversion *+lue, red and green)
!ta+le *little photo+leaching)
Diagnostic 'pplications in ioimaging and !ensing in/icroscopy, 0lo Cytometry, L1!', 0luorescent 1magingsystems, /R1 contrast agent
Therapeutic 'pplications in 2ene therapy, Drug Delivery!ystems, "hotodynamic Therapy, and Direct Cancer Therapy
-
7/24/2019 Nanotechnology in Biomedical Research
4/17
First Generation of NanoclinicsFirst Generation of Nanoclinics
Cancer diagnosis and targeted therapy
-
7/24/2019 Nanotechnology in Biomedical Research
5/17
Luteinizing Hormone!eleasing Hormone "LH!H#Luteinizing Hormone!eleasing Hormone "LH!H#
$argeted Nanoclinic$argeted Nanoclinic
!ilica
LHRH
&anoclinic
To photon dye
1ron #%ide
LHRH
LHRH
-
7/24/2019 Nanotechnology in Biomedical Research
6/17
%pta&e of LH!HNanoclinics in MCF' Cells%pta&e of LH!HNanoclinics in MCF' Cells
3min 27min21min15min9min
"articles saturation ith time
T"L!/ image of
+reast carcinoma cells.
The arro shos
nanoparticles
accumulating on and
inside the cell.
transmission Fluorescence
-
7/24/2019 Nanotechnology in Biomedical Research
7/17
0
1
2
3
4
5
6
0
1
2
3
4
5
6
-
+
+
LH-RH
LH-RH
LH-RH
Num
ber
ofCe
lls
Lysed
(10
4!
"2
#rs$
2
#rs$
%C
&-10"
'C-"
'
C-"
%C
&-10"
Num
ber
ofCe
lls
Lysed
(10
3!
Specificity of Magnetocytolysis by NanoclinicsSpecificity of Magnetocytolysis by Nanoclinics
Nanoclinics incubated (ith adherent cell for )* hours+ Cells (ashed, released by
trypsinization and sub-ected to .C magnetic field+ Magnetocytolysis determined by
counting remaining cells+
MCF'/ Human breast carcinoma LH!H receptor positi0e%C123'/ Human uterine carcinoma-LH!H receptor negati0e
-
7/24/2019 Nanotechnology in Biomedical Research
8/17
0
2
4
6
)
10
12 -*C LH-RH + LH-RH
Num
bero
fLyse
dCe
lls
(10
3!
4ffect of %p and .o(n !egulation of the LH!H !eceptors4ffect of %p and .o(n !egulation of the LH!H !eceptors
on Magnetocytolytic Acti0ity of LH!HNanoclinicson Magnetocytolytic Acti0ity of LH!HNanoclinics
4GF "epidermal gro(th factor# 5 upregulation
!C263 "synthetic somatostatin# 5 do(nregulation
-
7/24/2019 Nanotechnology in Biomedical Research
9/17
Surface $opography of MCF' Cells 1ncubated (ithSurface $opography of MCF' Cells 1ncubated (ith
LH!HNanoclinics AFMLH!HNanoclinics AFM
-
7/24/2019 Nanotechnology in Biomedical Research
10/17
/*au)
H*2auss)
.3
.$
.4
.5
6
6.3
( 6 6( 3 3(
a
a
ab
b
"articles ith cells
"articles in media
b
a +
Free particlesCell Bound particles
cell cell
4ffect of Cellular 1nteraction4ffect of Cellular 1nteraction
Magnetic 7roperties of NanoclinicsMagnetic 7roperties of Nanoclinics
-
7/24/2019 Nanotechnology in Biomedical Research
11/17
Tm78+983#:
r983#:r78+983#:
%pcon0ersion 4mission by%pcon0ersion 4mission by
!areearth Nanophosphors!areearth Nanophosphors
Tm - thulium
r - er+ium
8+ - ytter+ium
83#:- yttrium o%ide
-
7/24/2019 Nanotechnology in Biomedical Research
12/17
%con,erin. Nanoec#nolo.y for%con,erin. Nanoec#nolo.y for
/io-&ma.in./io-&ma.in.
; Cellsmission from
&anophosphor
; Cells and
mission from
&anophosphor
-
7/24/2019 Nanotechnology in Biomedical Research
13/17
$4M of .NA.oped Ca78$4M of .NA.oped Ca78**NanoparticlesNanoparticles
-
7/24/2019 Nanotechnology in Biomedical Research
14/17
In VitroIn Vitro$ransfection 4fficiency of$ransfection 4fficiency of
.NA.oped Ca78.NA.oped Ca78** NanoparticlesNanoparticles
Cell line 9 :ur&at
.NA 5 pS;
gal "
galactosidase#7ositi0e Control 5 Superfect See acknowledgementsSee acknowledgements
-
7/24/2019 Nanotechnology in Biomedical Research
15/17
In VivoIn Vivo$ransfection (ith .NA.oped Ca78$ransfection (ith .NA.oped Ca78**Nanoparticles andNanoparticles and
GalactoseSurface Modified .NA.oped Ca78GalactoseSurface Modified .NA.oped Ca78**NanoparticlesNanoparticles
!ee ac
-
7/24/2019 Nanotechnology in Biomedical Research
16/17
ConclusionsConclusions
Nanoclinics pro0ide the follo(ing ad0antages/
/ultifunctional nanoparticulate platform
!urface modifia+le for coupling of targeting agents Can carry different payloads *Therapeutic or 1maging)
Can e%ert therapy using e%ternal activation
>p-conversion +ioimaging ith reduced +ac
-
7/24/2019 Nanotechnology in Biomedical Research
17/17
Ac&no(ledgementsAc&no(ledgements
$he gene transfer studies (ere performed by .r+ 1 !oyunder the direction of /
Dr. '.&. /aitra
Department of Chemistry
>niversity of Delhi
Delhi, 1ndia
as partial re